Nine Products Pass Qualification Review for Inclusion in Fujian Province's October 2025 Sunshine Procurement List

Yesterday, the Fujian Provincial Medical Device Joint Procurement Center released the "Notice on the Public Disclosure of the List of Products Passed the Qualification Review for the 2025 October Supplementary Sunshine Procurement Catalogue," disclosing the list of products that passed the qualification review for the supplementary sunshine procurement catalogue as of October 2025, which has drawn attention from the industry.

According to the review, a total of 9 products have passed the qualification audit this time, mainly chemical drugs, with only one traditional Chinese medicine product, which is an external patch, including Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules, Erdafitinib Tablets, Pediatric Niuhuang Antipyretic Patch, Piroxiclib Tablets, Zolitinib Hydrochloride Tablets, Lisoclotril Tablets, Atrasentan Hydrochloride Tablets, Masegloxavir Tablets, and Zemitiostat Tablets. Among them, the manufacturer of Erdafitinib Tablets is Janssen-Cilag SpA, submitted by Xian Janssen Pharmaceutical Ltd.; the manufacturer of Atrasentan Hydrochloride Tablets is AbbVie Ireland NL B.V., submitted by Beijing Novartis Pharma Co., Ltd.

The Notice clarifies that the public announcement period will be from November 27 to December 3. If there are any objections, the informant is required to provide authentic, valid, and targeted evidence, and submit it through the "Enterprise Appeal" or "Enterprise Complaint" modules of the procurement subsystem within the announcement period.